The AhR inhibitor HP163, developed by Hercules Pharmaceuticals, reduced tumor growth in oral, breast, and skin orthotopic tumor models, and was shown to decrease immunosuppressive CD11b+ cells in the draining lymph nodes of oral squamous cell cancer [123]. Here, AHR is linked to neoplasm.